Disease · MONDO_0005180
Comparisons in its trials204
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 204
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Creatine vs Placebo: serious adverse events | 315 of 874 | 347 of 867 | 1,741 | NCT00449865 | Trial comparisons |
| Perampanel (Perampanel 2 mg or 4 mg During Core Study) vs Perampanel (Placebo During Core Study): serious adverse events | 57 of 664 | 33 of 333 | 997 | NCT00360412 | Trial comparisons |
| Carbidopa/Levodopa/Entacapone vs Carbidopa/Levodopa: serious adverse events | 91 of 373 | 84 of 371 | 744 | NCT00099268 | Trial comparisons |
| Carbidopa/Levodopa/Entacapone vs Carbidopa/Levodopa: Occurrence of Wearing-off | 139 of 305 | 161 of 333 | 638 | NCT00099268 | Trial comparisons |
| Carbidopa/Levodopa/Entacapone vs Carbidopa/Levodopa: Occurrence of Dyskinesia | 128 of 307 | 103 of 318 | 625 | NCT00099268 | Trial comparisons |
| Exelon Capsule vs Exelon Patch: serious adverse events | 87 of 294 | 83 of 288 | 582 | NCT00623103 | Trial comparisons |
| DBT Period: Prasinezumab vs DBT Period: Placebo: DBT Period: Number of Participants With Infusion Related Reactions (IRRs) | 32 of 292 | 37 of 290 | 582 | NCT04777331 | Trial comparisons |
| DBT Period: Prasinezumab vs DBT Period: Placebo: DBT Period: Number of Participants With Treatment Discontinuation Due to AEs | 2 of 292 | 3 of 290 | 582 | NCT04777331 | Trial comparisons |
| DBT Period: Prasinezumab vs DBT Period: Placebo: DBT Period: Number of Participants With Adverse Events of Special Interest (AESI) | 0 of 292 | 0 of 290 | 582 | NCT04777331 | Trial comparisons |
| DBT Period: Prasinezumab vs DBT Period: Placebo: deaths from any cause | 1 of 292 | 2 of 290 | 582 | NCT04777331 | Trial comparisons |
| DBT Period: Prasinezumab vs DBT Period: Placebo: serious adverse events | 34 of 292 | 34 of 290 | 582 | NCT04777331 | Trial comparisons |
| Early Pramipexole vs Delayed Pramipexole: serious adverse events | 25 of 261 | 25 of 274 | 535 | NCT00321854 | Trial comparisons |
| Patients From 248.524 vs Patients From 248.636: serious adverse events | 53 of 368 | 21 of 143 | 511 | NCT00601523 | Trial comparisons |
| Tavapadon vs Placebo: deaths from any cause | 1 of 252 | 0 of 255 | 507 | NCT04542499 | Trial comparisons |
| Tavapadon vs Placebo: serious adverse events | 17 of 252 | 14 of 255 | 507 | NCT04542499 | Trial comparisons |
| Sarizotan vs Placebo: serious adverse events | 23 of 252 | 25 of 252 | 504 | NCT00105508 | Trial comparisons |
| Pramipexole ER vs Pramipexole IR: serious adverse events | 6 of 234 | 13 of 239 | 473 | NCT01191944 | Trial comparisons |
| CVT-301 vs Observational Cohort: deaths from any cause | 1 of 271 | 0 of 127 | 398 | NCT02352363 | Trial comparisons |
| CVT-301 vs Observational Cohort: serious adverse events | 42 of 271 | 13 of 127 | 398 | NCT02352363 | Trial comparisons |
| IPX066 vs Carbidopa-Levodopa: serious adverse events | 11 of 201 | 5 of 192 | 393 | NCT00974974 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005180/comparisons